INT230-6 not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “INT230-6 is a fixed combination of cisplatin, vinblastine and SHAO.”In the company’s words, NCT06263231 on ClinicalTrials.gov
- Tested for
- Sarcoma,Soft Tissue
- Main trialPhase 3
- “To compare Overall Survival (OS) for INT230-6 vs United States (US) Standard of Care (SOC) in participants with unresectable or metastatic liposarcoma, undifferentiated pleomorphic sarcoma or leiomyosarcoma who have disease progression prior to study enrollment following no more than 2 standard therapies, which must have included an anthracycline-based regimen, unless contraindicated, and then a maximum of 1 additional regimen.”In the company’s words, NCT06263231 on ClinicalTrials.gov
Other drugs for Sarcoma,Soft Tissue
- AL3818Advenchen Laboratories, LLC · Phase 3
- LurbinectedinJazz Pharmaceuticals · Phase 3
- TBI-1301Takara Bio Inc. · Phase 3
- AdAPT-001EpicentRx, Inc. · Phase 2
- HS-20093Hansoh · Phase 2
- GotistobartOncoC4 · BioNTech · Phase 1/2
Coming up1
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Dec 2027 | A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) | |
| Phase 1/2Completed | 22 Feb 2023 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026